MRI-guided transurethral ultrasound ablation (TULSA) for localized prostate cancer: a single-center evaluation of 300 patients

This study evaluates MRI-guided transurethral ultrasound ablation (TULSA) for localized prostate cancer in 300 patients. TULSA treatments were performed using MRI for planning and real-time guidance, allowing for precise targeting and temperature monitoring. Safety outcomes were favorable, with mainly low-grade complications. Functional outcomes showed preserved erectile function and improved urinary symptoms over time. Oncological control was assessed using PSA, MRI, and biopsy, with a subset of patients requiring salvage therapy or further monitoring. The results demonstrate that TULSA is a safe and effective minimally invasive treatment option for localized prostate cancer, offering the potential for reduced morbidity compared to traditional therapies. This advanced technology combines the benefits of MRI imaging with targeted ultrasound energy delivery, showcasing the potential of image-guided interventions in urological applications.